Groundbreaking Discovery: Small Molecules That Suppress Breast Cancer by Targeting the Prolactin Receptor

👩‍⚕️ Presented by: Dr. Nira Ben-Jonathan, University of Cincinnati, USA

📣 Presentation Type: Oral (In-Person)
Title: Suppression of breast cancer by small molecules that block the prolactin receptor

🔍 Revolutionizing Breast Cancer Treatment

Breast cancer continues to challenge researchers worldwide, but new insights are paving the way for innovative treatments. Dr. Nira Ben-Jonathan, an eminent cancer biologist from the University of Cincinnati, presents an exciting pre-clinical breakthrough — small molecules capable of blocking the prolactin receptor (PRLR) and halting tumor growth.

💡 Key Findings & Scientific Insights

  • 🔸 Discovery of Novel Inhibitors: Two small molecule inhibitors, SMI-1 and SMI-6, were identified through high-throughput screening of 51,000 compounds.
  • 🔸 Precise Mechanism: Both molecules effectively bind to the prolactin receptor, disrupting its role in tumor cell proliferation and invasion.
  • 🔸 Powerful Selectivity: SMI-6 stands out for targeting malignant breast cancer cells while sparing normal, healthy cells.
  • 🔸 Preclinical Success: In animal models, SMI-6 dramatically reduced breast cancer tumor growth with no visible toxicity.
  • 🔸 Therapeutic Advantages: Oral deliverability, potential brain penetration (for metastases), and ease of optimization make SMI-6 a strong candidate for future cancer therapies.

🌿 Why This Study Matters

Prolactin, a hormone produced in both the pituitary and other tissues, has been known to promote cancer growth. By blocking its receptor, Dr. Ben-Jonathan’s team introduces a new strategy to prevent tumor progression and enhance treatment selectivity — marking a significant step toward targeted, non-toxic cancer therapies.

👩‍🔬 About Dr. Nira Ben-Jonathan

A highly respected leader in cancer biology, Dr. Ben-Jonathan’s career is decorated with achievements:

  • Authored over 180 scientific papers and 12 textbook chapters.
  • Fellow of the AAAS and Royal Society of Medicine.
  • Recipient of the NIH Research Career Development Award, Rieveschl Award, and Merker Lectureship in Translational Endocrinology.
  • Served on multiple NIH, DOD, and Komen Foundation committees, and chaired five NIH Study Sections.

Her research continues to shape the understanding of hormonal regulation in cancer biology and inspire future generations of scientists.


🌏 Join the Global Cancer Science Community

Be part of the International Conference on Cancer Science and Research (ICCSR 2025) — a hybrid event uniting global experts to discuss breakthroughs in cancer prevention, diagnosis, and therapy.

🎓 Event: International Conference on Cancer Science and Research
📅 November 17–19, 2025 | 📍 Singapore & Online
🔗 Visit Official Website

👉 Register Now: https://cancer.miconferences.com/register
🧬 Submit Your Abstract: https://cancer.miconferences.com/abstract-submission
📧 Email: cancer@mathewsconference.com | 📞 +1 (312) 462-4448
💬 WhatsApp: +1 (424) 377 0967
🐦 Follow on X: @CancerWorldConf

#BreastCancerResearch #CancerScience2025 #ProlactinReceptor #CancerTherapy #SMI6 #OncologyInnovation #CancerConference #SingaporeConference #CancerAwareness #DrugDiscovery #CancerBiology #MathewsConferences #CancerTreatment #OncologyResearch #BreastCancerAwareness

New Hope Against Oral Cancer: Thienopyrimidines Show Strong Selectivity in Targeting Tumor Cells

Oral cancer continues to be a major health challenge worldwide, with oral squamous cell carcinoma (OSCC) ranking among the most aggressive and difficult-to-treat cancers of the head and neck. A new study by Prof. Biliana Nikolova and her research team at the Bulgarian Academy of Sciences has introduced a promising direction in selective cancer therapy using thienopyrimidine-based compounds.

Title: Targeting oral squamous cell carcinoma with thienopyrimidines

🧬 Research Insight

The research explored seven novel 2-substituted 4-amino-thieno[2,3-d]pyrimidines—originally designed as DPP-4 inhibitors—for their cytotoxic and selective effects against oral cancer cells. Tests were performed on SCC-9 and HSC-3 cell lines, along with normal HaCaT keratinocytes to evaluate compound safety and specificity.

🌟 Major Findings

  • Compound 6 stood out with the highest selectivity index (SI = 22.3 for SCC-9 and SI = 6.4 for HSC-3), showing strong anticancer potential.
  • Compound 4 also displayed impressive selectivity (SI = 12.8), while compound 5 performed comparably to doxorubicin.
  • Advanced biophysical analyses, including FACS, colony-forming, and cell migration assays, confirmed their ability to inhibit cancer cell growth and spread.
  • The study highlights compound 6 as a lead candidate for further development as a selective oral cancer therapeutic with reduced side effects on normal cells.

👩‍🔬 About the Scientist

Prof. Biliana Nikolova is a distinguished biophysicist specializing in the impact of electric fields and nanomedicine applications in cancer therapy. At the Institute of Biophysics and Biomedical Engineering, she leads pioneering research that bridges biophysics, electrotherapy, and biomedical engineering. Her work continues to inspire new strategies in targeted cancer treatment and tissue regeneration.


🌍 Presented At

🧫 International Conference on Cancer Science and Research
📅 November 17–19, 2025 | Singapore & Online
🌐 https://cancer.miconferences.com/

#OralCancerResearch #CancerScience #Biophysics #Thienopyrimidines #CancerInnovation #CancerTherapy #BiomedicalResearch #OSCC #CancerWorldConf #Cancer2025 #OncologyUpdates #CancerConferenceSingapore

Breaking Barriers in Breast Cancer Therapy: How 2NF and Safingol Work Together to Stop Tumor Growth

A remarkable new study by Dr. Viviana C. Blank from the University of Buenos Aires, Argentina, shines light on a powerful drug combination that could change the way we treat breast cancer. Her research uncovers how two compounds — 2´nitroflavone (2NF) and safingol — work together to attack cancer cells through multiple molecular pathways.

Dr. Blank will be presenting her latest findings at the upcoming International Conference on Cancer Science and Research, happening November 17–19, 2025, in Singapore and Online.

🎯 Title: Synergistic antitumor effects of 2NF and safingol combination in breast cancer: Molecular mechanisms involving SPHK1, MAPKs, and ER stress

🔍 What Makes This Research Stand Out

The study focuses on disrupting the SPHK1/sphingosine-1-phosphate (S1P) signaling axis — a crucial mechanism that helps cancer cells survive and multiply. By combining 2NF, a flavonoid with known anticancer potential, and safingol, a sphingosine kinase inhibitor, Dr. Blank and her team observed remarkable synergistic antitumor effects in breast cancer models.

⚗️ Key Discoveries from the Study

·         🧬 Molecular Targeting: 2NF directly interacts with SPHK1 near the Ser225 site, preventing phosphorylation and blocking its translocation to the cell membrane.

·         💥 Enhanced Tumor Cell Death: The 2NF and safingol combination significantly reduces cancer cell proliferation and promotes apoptosis.

·         🔬 MAPK Activation: The dual treatment triggers key signaling pathways — p38, JNK, and ERK MAPKs — which play a central role in cell stress and death.

·         ⚙️ ER Stress Induction: The combination boosts endoplasmic reticulum (ER) stress responses, further contributing to tumor cell destruction.

·         🧪 Therapeutic Implication: Findings suggest a multi-targeted therapeutic approach could be more effective than single-drug treatments in breast cancer management.

👩‍🔬 About Dr. Viviana C. Blank

Dr. Blank is a biochemist and senior researcher at the University of Buenos Aires and a member of CONICET. She holds a Ph.D. in Biological Chemistry and has dedicated her career to exploring flavonoids and synthetic molecules with anticancer activity.
Her passion lies in uncovering molecular mechanisms of tumor inhibition and developing potential therapeutic strategies that can improve patient outcomes.

🧭 Conference Information

📅 Dates: November 17–19, 2025
📍 Venue: Singapore & Online (Hybrid Event)
🎓 Event: International Conference on Cancer Science and Research
🌐 Website: https://cancer.miconferences.com/
📝 Register Here: https://cancer.miconferences.com/register
💬 Submit Abstract: https://cancer.miconferences.com/abstract-submission
📧 Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448
📱 WhatsApp: +1 (424) 377 0967
🐦 Follow Updates: @CancerWorldConf

#CancerScience2025 #CancerResearch #BreastCancerAwareness #AntitumorMechanisms #MolecularBiology #SPHK1 #MAPKPathway #ERStress #FlavonoidResearch #Safingol #BiomedicalInnovation #UniversityOfBuenosAires #WomenInScience #ScientificDiscovery #OncologyResearch #CancerWorldConf

Transforming Biopsy: Dr. Dmitri Lapotko Unveils Real-Time Cancer Detection Breakthrough

In a remarkable leap toward the future of cancer diagnostics, Dr. Dmitri Lapotko of Scorpido Photonics, Inc, USA, will present his groundbreaking work on “Instant High-Sensitivity Non-Invasive In-Vivo Diagnosis During Biopsy” at the International Conference on Cancer Science and Research, taking place November 17–19, 2025, in Singapore and Online.

Traditional biopsies, though considered the gold standard for cancer diagnosis, often face challenges — invasive procedures, delayed results, and missed microscopic tumors. Dr. Lapotko’s innovation changes that narrative. His Plasmonic Nanobubble (PNB) Diagnostic System enables doctors to detect even microscopic tumors instantly and non-invasively, directly at the tip of a biopsy needle.

🔬 Key Highlights of the Presentation:

·         Instant Tumor Detection: The PNB system allows real-time, in-vivo identification of tumors during biopsy without tissue removal.

·         High Sensitivity & Specificity: Delivers precise and rapid diagnostic results, minimizing false negatives.

·         Automation-Ready Technology: Supports AI-driven interpretation, reducing human error and ensuring consistent outcomes.

·         Universal Application: Compatible with all biopsy types — needle, endoscopic, surgical, or robotic — for diverse cancer forms.

·         Empowering Low-Resource Clinics: Designed for accessibility, enabling early cancer detection even in limited-resource healthcare settings.

·         Revolutionizing Patient Care: Turns standard biopsy procedures into an instant diagnostic experience, speeding up treatment decisions.

👨‍🔬 About Dr. Dmitri Lapotko:

A distinguished researcher in biophotonics and nanotechnology, Dr. Lapotko holds a Ph.D. in Laser Defense Applications and a Doctor of Science in Bioengineering. His pioneering invention — laser-generated plasmonic nanobubbles — has become a cornerstone for next-generation diagnostic, therapeutic, and surgical innovations in oncology.


📅 Event Details:
Conference: International Conference on Cancer Science and Research
Dates: November 17–19, 2025
Venue: Singapore & Online
🌐 Website: https://cancer.miconferences.com/

📩 Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448
💬 WhatsApp: +1 (424) 377 0967
🐦 X (Twitter): @CancerWorldConf

🔗 Register Here: https://cancer.miconferences.com/register
🧾 Submit Abstract: https://cancer.miconferences.com/abstract-submission

#CancerConference2025 #CancerInnovation #CancerDiagnostics #PlasmonicNanobubbles #OncologyResearch #Biophotonics #Nanotechnology #InVivoDiagnosis #CancerScience #MedicalInnovation #MathewsConferences #SingaporeEvents

ANT2–ATP Synthasome: Powering the Mitochondrial Engine of Breast Cancer Progression

Presenter: Dr. Chia-Jung Li, Kaohsiung Veterans General Hospital, Taiwan

Presentation Type: Poster (In-Person)


Title: Functional Integration of the ATP Synthasome Drives Mitochondrial Efficiency in Breast Carcinoma

🔍 Overview

Breast cancer cells possess an extraordinary ability to adapt their energy metabolism, supporting aggressive growth and metastasis. Dr. Chia-Jung Li’s latest research dives into the mitochondrial mechanisms behind this transformation — focusing on the adenine nucleotide translocase 2 (ANT2) protein and its association with the ATP synthasome complex.

The study provides new evidence showing how functional integration between ANT2 and ATP5B boosts mitochondrial efficiency, powering the metastatic potential of breast cancer cells.

🌟 Key Research Highlights

·         ANT2 Overexpression in Aggressive Tumors:
Elevated ANT2 levels were linked to poor survival outcomes and increased metastatic activity in breast cancer tissues.

·         Functional Role in Energy Production:
ANT2 knockdown significantly reduced ATP generation, OXPHOS activity, and cell invasion, revealing its central role in tumor metabolism.

·         Therapeutic Discovery – Cymarin:
Through pharmacogenomic screening, cymarin emerged as a potent ANT2 inhibitor, effectively reducing tumor growth and metastasis in preclinical models.

·         Mitochondrial Network Insights:
ANT2 was found to interact with ATP5B, forming a powerful ATP synthasome that enhances energy flux in invasive cancer cells.

·         Clinical Implications:
Targeting ANT2 could be a breakthrough strategy to disrupt mitochondrial energy flow, limiting cancer progression and improving patient outcomes.

👨‍🔬 About the Researcher

Dr. Chia-Jung Li is a distinguished mitochondrial biologist and cancer researcher from Taiwan, renowned for his work on mitochondrial dysfunction, cellular metabolism, and aging-related diseases. With over 130 SCI-indexed publications, his research bridges fundamental biochemistry with translational oncology — driving new directions in mitochondria-targeted therapies.


🌐 Conference Information

📍 Event: International Conference on Cancer Science and Research
📅 Dates: November 17–19, 2025
🏛️ Venue: Singapore & Online (Hybrid)
🔗 Event Website
📧 Email: cancer@mathewsconference.com
📞 Phone: +1 (312) 462-4448
💬 WhatsApp: +1 (424) 377 0967
🐦 X (Twitter): @CancerWorldConf
📝 Submit Abstract | Register Now

#ANT2 #BreastCancerResearch #MitochondrialFunction #CancerMetabolism #ATP #OXPHOS #CancerTherapy #Mitochondria #Cymarin #Metastasis #OncologyConference #CancerScience2025 #SingaporeConference #CancerResearchInnovation

Subscribe to: Comments (Atom)